Skip to content

Instant Intelligence for Biotech Investors

Home
Tools
Alerts
About
Join ScanScor
Log In
- Panel

ScanScor

Biotech Breakout Alerts and Predictions

ScanScor

Biotech Breakout Alerts and Predictions

Predictions
Scores
News Stream

FDA-filing

AI Biomed Predictions

MNPR – Mid-2026 NDA filing could reignite Monopar’s rare-disease rally

ScanScor Admin / June 9, 2026

Search

Tools

Predictions
Scores
News Stream

Recent Comments

Recent Comments

3 days ago CRDF – ASCO Data Could Deci... – BROKEN is defensible, but I would make it a specific kind... by ScanScor Admin
4 days ago GTBP – GTB-5550 clinical la... – GTBP — Does not qualify for a new prediction today. Reas... by ScanScor Admin
5 days ago CRDF – ASCO Data Could Deci... – Our NDAPR parser choked on the response that included a p... by ScanScor Admin
7 days ago LXRX – Lexicon Gears Up for... – Original thesis: BROKEN Reason: It was built around ... by ScanScor Admin
2 weeks ago MNOV – MediciNova Set for S... – MNOV – WATCH ACTIVE Catalyst: MN-001 Phase 2 top-line da... by ScanScor Admin

Recent Posts

CRBP – Corbus Faces Its Next Real Repricing on TEMPO-1 Launch
MNPR – Mid-2026 NDA filing could reignite Monopar’s rare-disease rally
ATYR – June IND reset could spark aTyr’s post-failure rebound
ZNTL – ASCO follow-through could spark Zentalis’ next ovarian cancer rerating
UNCY – UNCY Faces Make-or-Break FDA Catalyst With Approval Upside

ScanScor empowers traders and investors with instant
AI-driven access to trusted intelligence.

🧠 Powered by real-time AI
🔍 Trained to find the moment before it moves

Terms and Conditions
About
Join the ScanScor Revolution

Disclaimer: ScanScor provides research and educational information only. Nothing on this site is financial advice or a recommendation to buy or sell securities. ScanScor does not provide forecasts or guarantee any outcomes. Past performance is not indicative of future results.

Copyright © 2026 ScanScor

Best viewed on desktop. Mobile optimization coming soon.

Scroll to Top